Gilead says breast cancer drug succeeded in key study, but offers few details

Gilead said Monday that the drug at the center of its largest-ever acquisition has succeeded in a key clinical trial, though, for some, the company's decision to not disclose specific data raises doubts about how impactful its treatment could be.